Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 7:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 1,618 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Retinal Disease Clear all
Terminated Phase 2 Interventional Results available

The Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular Degeneration

NCT00857259
View directory record Official record
Conditions
Choroidal Neo-Vascular Age-onset Macular Degeneration, Age-related Macular Degeneration
Interventions
Everolimus, Ranibizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
4
States / cities
Beverly Hills, California • Sacramento, California • Denver, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2011 · Synced Oct 24, 2026, 7:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Tracking Optical Coherence Tomography

NCT00343603
View directory record Official record
Conditions
Macular Degeneration, Glaucoma, Diabetic Retinopathy, Choroidal Disease
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Oct 24, 2026, 7:29 AM EDT
Active, not recruiting Phase 3 Interventional

4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

NCT06864988
View directory record Official record
Conditions
Macular Neovascularization Secondary to Age-Related Macular Degeneration
Interventions
4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL)
Biological
Lead sponsor
4D Molecular Therapeutics
Industry
Eligibility
50 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
91
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Springdale, Arkansas + 79 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 24, 2026, 7:29 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Pilot Study of X-82 in Patients With Wet AMD

NCT01674569
View directory record Official record
Conditions
Exudative Macular Degeneration
Interventions
X-82 oral, ranibizumab (Lucentis)
Drug
Lead sponsor
Tyrogenex
Industry
Eligibility
50 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
5
States / cities
Beverly Hills, California • New London, Connecticut • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 24, 2026, 7:29 AM EDT
Completed Phase 2 Interventional Results available

A Study of an Encapsulated Cell Technology (ECT) Implant for Patients With Atrophic Macular Degeneration

NCT00447954
View directory record Official record
Conditions
Nonexudative Age-Related Macular Degeneration, Unspecified Eye, Intermediate Dry Stage
Interventions
High Dose NT-501 implant, Low Dose NT-501 implant, Sham
Combination Product · Other
Lead sponsor
Neurotech Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Beverly Hills, California • Hollywood, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 24, 2026, 7:29 AM EDT
Completed Phase 1 Interventional

The Treatment of Uveitic Cystoid Macular Edema With Topical Interferon Gamma

NCT00943982
View directory record Official record
Conditions
Uveitis
Interventions
Interferon Gamma 1-b
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 24, 2026, 7:29 AM EDT
Active, not recruiting No phase listed Observational

Extension Study to Evaluate the Long-Term Outcomes of Pediatric Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study (Acronym: Butterfleye Next)

NCT04515524
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Non-Interventional
Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
11 Months to 5 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
9
States / cities
La Jolla, California • Loma Linda, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 24, 2026, 7:29 AM EDT
Not listed Not applicable Interventional

A Research Study to Evaluate the Effects of Repeated Intravitreal Injections on Bacteria Around the Eye

NCT01531842
View directory record Official record
Conditions
Central Retinal Vein Occlusion, Choroidal Neovascularization, Age-related Macular Degeneration, Branch Retinal Vein Occlusion
Interventions
Conj flora Antibiotic resistance
Procedure
Lead sponsor
Mid Atlantic Retina
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 13, 2012 · Synced Oct 24, 2026, 7:29 AM EDT
Completed Phase 4 Interventional Results available

Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab

NCT02559180
View directory record Official record
Conditions
Diabetic Retinopathy, Macular Edema
Interventions
aflibercept
Drug
Lead sponsor
Rishi Singh
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Oct 24, 2026, 7:29 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib

NCT00242580
View directory record Official record
Conditions
Macular Degeneration, Choroidal Neovascularization
Interventions
Verteporfin photodynamic therapy, Pegaptanib, Triamcinolone acetonide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2016 · Synced Oct 24, 2026, 7:29 AM EDT
Completed Phase 2 Interventional Results available

Choroideremia Gene Therapy Clinical Trial

NCT02553135
View directory record Official record
Conditions
Choroideremia
Interventions
Injection of AAV2-REP1 (10e11 vg)
Biological
Lead sponsor
Byron Lam
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Oct 24, 2026, 7:29 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies

NCT01109394
View directory record Official record
Conditions
Sarcoma, Endocrine Tumors, Neuroblastoma, Retinoblastoma, Renal Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
4 Weeks and older
Enrollment
6,035 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Orange, Florida • Bethesda, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 24, 2026, 7:29 AM EDT
Completed No phase listed Observational

Bedside Optical Retinal Assessment of Hypoxic Ischemic Encephalopathy in Infants

NCT03640494
View directory record Official record
Conditions
Hypoxic-Ischemic Encephalopathy
Interventions
Optical Coherence Tomography
Device
Lead sponsor
Duke University
Other
Eligibility
Up to 20 Days
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Durham, North Carolina • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 24, 2026, 7:29 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Moran AMD Genetic Testing Assessment Study

NCT05265624
View directory record Official record
Conditions
Age-Related Macular Degeneration, Genetic Testing, Nutritional Biomarkers
Interventions
Early disclosure of genetic testing results, Late disclosure of genetic testing results
Behavioral
Lead sponsor
Paul S. Bernstein
Other
Eligibility
18 Years to 64 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 24, 2026, 7:29 AM EDT
Terminated Phase 1Phase 2 Interventional

Macugen to Prevent Worsening of Macular Edema Following Cataract Surgery in Diabetics

NCT00346983
View directory record Official record
Conditions
Cystoid Macular Edema
Interventions
Pegaptanib sodium, Control
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 12, 2008 · Synced Oct 24, 2026, 7:29 AM EDT
Completed No phase listed Observational

Age-Related Macular Degeneration, Scotopic Dysfunction, and Driving Performance in a Simulator

NCT03166202
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
60 Years to 95 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 6, 2019 · Synced Oct 24, 2026, 7:29 AM EDT
Completed Phase 1 Interventional

Vitamin E to Treat Uveitis-Associated Macular Edema

NCT00021645
View directory record Official record
Conditions
Cystoid Macular Edema, Uveitis
Interventions
Vitamin E
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 24, 2026, 7:29 AM EDT
Completed Phase 1 Interventional

Laser and Antioxidant Treatment of Diabetic Macular Edema

NCT00055042
View directory record Official record
Conditions
Macular Edema, Diabetes Mellitus
Interventions
Vitamin E
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 24, 2026, 7:29 AM EDT
Terminated Phase 2 Interventional Results available

Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma

NCT01471054
View directory record Official record
Conditions
Macular Edema, Cystoid Macular Edema, Uveal Melanoma, Radiation Maculopathy, Radiation Retinopathy
Interventions
Ozurdex, Bevacizumab
Drug
Lead sponsor
Arman Mashayekhi
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Oct 24, 2026, 7:29 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Eye Drop Application Monitor, Pilot Study

NCT02639845
View directory record Official record
Conditions
Cataracts, Retina Surgery, Glaucoma, Any Condition That Requires Ophthalmic Drops
Interventions
Not listed
Lead sponsor
Alexander Eaton
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Dec 28, 2015 · Synced Oct 24, 2026, 7:29 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Diabetic Macular Edema and Diabetic Retinopathy Screening (TeleMed) With Automated Retinal Photography

NCT01790945
View directory record Official record
Conditions
Mild Nonproliferative Diabetic Retinopathy, Moderate Nonproliferative Diabetic Retinopathy, Severe Nonproliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy, Diabetic Macular Edema
Interventions
Not listed
Lead sponsor
Retina Institute of Hawaii
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Hilo, Hawaii
Source: ClinicalTrials.gov public record
Updated Feb 13, 2013 · Synced Oct 24, 2026, 7:29 AM EDT
Enrolling by invitation Not applicable Interventional

Adaptive Optics Scanning Light Ophthalmoscopy (AOSLO) and Microperimetry (MP) Sub-study

NCT07747662
View directory record Official record
Conditions
Geographic Atrophy
Interventions
Adaptive Optics Scanning Light Ophthalmoscopy, Microperimetry, Optical Coherence Tomography
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
50 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 24, 2026, 7:29 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Screening for Research Participants

NCT00655096
View directory record Official record
Conditions
Eye Diseases
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
2 Years to 100 Years
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 24, 2026, 7:29 AM EDT
Terminated Phase 3 Interventional Results available

A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

NCT02247479
View directory record Official record
Conditions
Geographic Atrophy
Interventions
Lampalizumab, Sham
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
906 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
76
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Oct 24, 2026, 7:29 AM EDT